175 related articles for article (PubMed ID: 36645031)
21. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
22. Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature.
Grecea M; Marabelle A; Ammari S; Massard C; Champiat S
Oncologist; 2020 May; 25(5):369-374. PubMed ID: 32091646
[TBL] [Abstract][Full Text] [Related]
23. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Wang Y; Ma R; Liu F; Lee SA; Zhang L
Front Immunol; 2018; 9():374. PubMed ID: 29556232
[TBL] [Abstract][Full Text] [Related]
24. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
[TBL] [Abstract][Full Text] [Related]
25. Preclinical platforms to study therapeutic efficacy of human γδ T cells.
Ou L; Wang H; Huang H; Zhou Z; Lin Q; Guo Y; Mitchell T; Huang AC; Karakousis G; Schuchter L; Amaravadi R; Guo W; Salvino J; Herlyn M; Xu X
Clin Transl Med; 2022 Jun; 12(6):e814. PubMed ID: 35731974
[TBL] [Abstract][Full Text] [Related]
26. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
[TBL] [Abstract][Full Text] [Related]
27. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms.
Huang MY; Jiang XM; Wang BL; Sun Y; Lu JJ
Pharmacol Ther; 2021 Mar; 219():107694. PubMed ID: 32980443
[TBL] [Abstract][Full Text] [Related]
29. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
Liu N; Zhang J; Yin M; Liu H; Zhang X; Li J; Yan B; Guo Y; Zhou J; Tao J; Hu S; Chen X; Peng C
Mol Ther; 2021 Jul; 29(7):2321-2334. PubMed ID: 33744468
[TBL] [Abstract][Full Text] [Related]
31. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Ai L; Xu A; Xu J
Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
[TBL] [Abstract][Full Text] [Related]
32. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
33. Melanoma: An immunotherapy journey from bench to bedside.
Navani V; Graves MC; Mandaliya H; Hong M; van der Westhuizen A; Martin J; Bowden NA
Cancer Treat Res; 2022; 183():49-89. PubMed ID: 35551656
[TBL] [Abstract][Full Text] [Related]
34. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
35. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
36. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
37. Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade.
Pang K; Shi ZD; Wei LY; Dong Y; Ma YY; Wang W; Wang GY; Cao MY; Dong JJ; Chen YA; Zhang P; Hao L; Xu H; Pan D; Chen ZS; Han CH
Drug Resist Updat; 2023 Jan; 66():100907. PubMed ID: 36527888
[TBL] [Abstract][Full Text] [Related]
38. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
39. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
